Table 2.
Treatment Characteristics
| Characteristic | No. of Patients (%) | ||
|---|---|---|---|
| WW (n = 32) | Surgery (n = 55) | P | |
| Induction chemotherapy | |||
| FOLFOX | 32 (100) | 54 (98) | |
| CapeOx | 0 | 1 (2) | - |
| No. of cycles of FOLFOX, median (range) | 8 (6–12) | 8 (4–10) | 0.55 |
| Radiation dose in Gy, median (range) | 50 (39–56) | 50 (45–62.5) | 0.76 |
| Sensitizing chemotherapy | |||
| Capecitabine | 0 | 3 (5) | |
| 5-FU | 32 (100) | 52 (95) | - |
| Toxicity during TNT (any) | 8 (25) | 19 (35) | 0.35 |
| Postoperative complicationsa | 8 (14) | - | |
| Ileus | 3 (1.6) | ||
| Anemia requiring transfusion | 2 (1.1) | ||
| Urinary infection | 1 (0.5) | ||
| Urinary retention | 1 (0.5) | ||
| SSI | 1 (0.5) | ||
a
Clavien-Dindo grade II.